InsiderStreet Equity Research

Produced by InsiderStreet.ai from live production data. It is not investment advice, not an offer or solicitation to buy or sell any security, and not a recommendation for any investor. Do not rely on it for any investment decision.

Last Close

$79.32

2026-10-16

Market Cap

$32.8B

Volume

5.1M

52-Wk High

$148.30

52-Wk Low

$68.77

Trailing PE

13.0

P/S

3.44

Gross Margin

70.9%

Net Margin

27.5%

ROE

69%

ROIC

22%

Piotroski

7/9

Altman Z

4.8

1-Yr Return

-44.4%

5-Yr Return

-33.7%

Zoetis Inc. stands as a global leader in animal health, focusing on the research, development, manufacturing, and commercialization of veterinary pharmaceuticals, vaccines, and diagnostic tools. Its comprehensive portfolio serves a broad spectrum of species, encompassing both livestock, including cattle, swine, poultry, fish, and sheep, and beloved companion animals such as dogs, cats, and horses. Among its pharmaceutical offerings are various therapeutic agents. This includes vaccines, vital for preventing respiratory, gastrointestinal, and reproductive diseases by stimulating a targeted immune response; anti-infectives that combat or inhibit the proliferation of bacterial, fungal, or protozoal pathogens; and parasiticides aimed at eradicating both internal and external pests such as fleas, ticks, and various worms. Additional pharmaceuticals address areas such as pain management and sedation, anti-emesis, reproductive health, and oncology. The portfolio also features dermatological solutions for allergic skin conditions and atopic dermatitis, alongside medicated feed additives specifically designed for livestock. Beyond therapeutics, Zoetis offers an extensive array of diagnostic solutions. These include portable analysis systems for blood and urine, point-of-care testing devices, specialized instruments and reagents, rapid immunoassay kits, comprehensive reference laboratory services, and blood glucose monitoring equipment. Further extending its reach, the company provides supplementary offerings such as nutritional products, agribusiness support services, biodevices, genetic testing, and innovations in precision animal health. Zoetis distributes its diverse product portfolio to a broad customer base, including veterinary professionals, livestock producers, and retail channels. This distribution occurs directly via its sales representatives and technical specialists, as well as through partnerships with third-party veterinary distributors. Established in 1952, the company maintains its corporate headquarters in Parsippany, New Jersey.

SectorHealthcareIndustryDrug Manufacturers - Specialty & GenericExchangeNYSEMarket Cap$32.8BEmployees14,500 (SEC-filed)CEOKristin C. PeckIPO2013-02-01CountryUS

10 Sylvan Way, Parsippany, NJ 07054 · Tel 973 822 7000 · zoetis.com

INSIDERSTREET SCORE66 / 100Street mean $86.17 (6 analysts, last qtr) — their number, not ours

INSIDER CONSENSUS SIGNALNET BUYING$0.9M open-market purchases vs $0.0M sales / 6 mo

1 Year vs S&P 500 · ZTS -44.4% · S&P 500 +15.9% · spread -60.3pp

7 Years vs S&P 500 · ZTS -33.7% · S&P 500 +189.9% · spread -223.5pp

Both charts indexed to 100 at the start of their window and drawn on a single shared scale, so the gap to the benchmark is the gap you see. Adjusted closes throughout.

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

INSIDERSTREET
SCORE66of 100

Score Breakdown

Profitability	98/100
Growth	47/100
Momentum	66/100
Quality	68/100
Earnings Quality	76/100
Balance Sheet	56/100
Value	71/100
Risk (safety)	100/100
Overall	66.0/100

Each component is a diagnostic reading on its own 0-100 scale. The overall score is computed separately from the underlying financials and is not the average of the rows above — components are not equally weighted and three of them (Momentum, Value, Risk) are derived partly from price rather than from the business.

Peer Comparison — IS Score

Symbol	IS Score
TEVA	40
VTRS	37
ELAN	26
ALKS	41
LNTH	66
AMRX	49
ZTS	66

IS Score Trend — quarterly

14 quarters, 23 Q1 to 26 Q2. Peak 73 in 24 Q3, latest 66 — -7 since. Fell in 3 of the last 4 quarters. Dashed line marks 40 on the 0-100 scale.

BUSINESS QUALITY66 / 100IS Score 66.0 / 100 · -7.1 from peak of 73

Fundamental factor model, quarterly. Measures how the business is doing - not where the price is going.

PRICE STRUCTUREBULLISHTechnical Score 82 / 100 · Power +64 · 20 of 22 indicator votes bullish

Vote share across trend, momentum, volume, volatility and pattern families. Describes where the price is, not where it is going.

Both readings sit above the midpoint — business quality at 66 and price structure at 82 out of 100 — so they are not in conflict. The fundamentals and the tape are saying the same thing, which is the case in which either one alone would have been enough.

Trigger	Where it stands now	What it would mean
IS Score reaches 75 and holds two consecutive quarters	now 66.0	would move us up one band
IS Score stops falling - one quarter higher than the prior	last four: 67 → 66 → 64 → 66	the direction matters more than the level
Technical vote share back above 50%	now 82%	price structure no longer broken
Institutional holder count rises two quarters running	peak 1,867 → now 1,427	fewer institutions willing to hold is our clearest warning

We publish these so the view can be shown to be wrong. If none of them move and our reading does, we owe you an explanation.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

This page is InsiderStreet's own reading, produced from the data in the rest of this document. It is not a price target and not investment advice. Analyst consensus and street price targets appear later under their own heading and are the street's numbers, not ours.

Site Convergence Score3 of 4top 4% of 29,420 symbols

Sources Aligned— of 3independent disclosures

Congress (180d)16 buys2026-09-18

Insider Buys (180d)3$0.89M

ETF Funds (30d)1368 up / 1178 downnet +190 funds

Congressional and insider figures are disclosed purchases in the trailing 180 days; ETF figures are COUNTS OF FUNDS whose holding changed in 30 days, not dollars. Coincidence of separate disclosures, not coordination. An absent source means nothing qualifying was disclosed in its window.

Institutions holding — 12 quarters

Peak 1,867 · latest 1,427 (-440 from peak).

Quarter	Holders	13F shares	Value	Reported own%	Guard
2026 Q2	1,427	400.0M	$28.5B	95.8%
2026 Q1	1,602	406.9M	$47.2B	97.4%
2025 Q4	1,662	433.8M	$50.7B	103.9%	ex-outlier 92.4%
2025 Q3	1,779	409.5M	$61.1B	98.1%
2025 Q2	1,848	421.3M	$64.6B	100.9%	ex-outlier 90.8%
2025 Q1	1,867	418.7M	$67.8B	100.3%
2024 Q4	1,848	417.3M	$66.7B	99.9%
2024 Q3	1,762	417.8M	$79.3B	100.0%
2024 Q2	1,719	422.4M	$71.5B	101.1%
2024 Q1	1,719	425.3M	$69.3B	101.8%
2023 Q4	1,722	426.4M	$80.5B	102.1%
2023 Q3	1,601	420.4M	$71.0B	100.7%

How to read ownership above 100%. A 13F reports the positions a manager has investment discretion over, and where two or more managers share discretion over the same block, each one reports it. Summed across filers, the total can therefore exceed the shares actually outstanding without anything being wrong. We publish the figure as filed rather than netting it down, and flag separately any quarter where the arithmetic is not merely high but impossible.

Why 2025-12 reads 103.87%. Institutions cannot hold more of a company than exists. The reported 433.8M shares exceed the 417.6M outstanding, and a single filer accounts for the excess: VANGUARD GROUP INC reports 47,780,974 shares against 42,306,764 the prior quarter, a 1x jump, which alone would be 11.4% of the company. Excluding that filing, ownership is 92.4%. We publish both figures. 13F filings are due 45 days after quarter end and amendments keep arriving after that, so the newest quarter is provisional by construction - this is what an unsettled quarter looks like.

Why 2025-06 reads 100.88%. Institutions cannot hold more of a company than exists. The reported 421.3M shares exceed the 417.6M outstanding, and a single filer accounts for the excess: VANGUARD GROUP INC reports 41,886,987 shares against 41,556,164 the prior quarter, a 1x jump, which alone would be 10.0% of the company. Excluding that filing, ownership is 90.8%. We publish both figures. 13F filings are due 45 days after quarter end and amendments keep arriving after that, so the newest quarter is provisional by construction - this is what an unsettled quarter looks like.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Insider	Role	Date	Type	Shares	Value	Post-Txn Owned
Peck Kristin C	director, Chief Executive Officer	2026-10-09	A-Award	720	—	66,915
Esch Kevin	Executive Vice President	2026-10-09	A-Award	360	—	1,167
Driscoll Rimma	Executive Vice President	2026-10-09	A-Award	278	—	6,551
Fuller Julie	Executive Vice President	2026-10-09	A-Award	368	—	2,480
Sarbaugh Keith	Executive Vice President	2026-10-09	A-Award	303	—	2,668
Ferran Astorga Jeannette	Executive Vice President	2026-10-09	A-Award	53	—	2,349
Nayak Abhay U	Executive Vice President	2026-10-09	A-Award	321	—	5,022
Lagano Roxanne	Executive Vice President	2026-10-09	A-Award	368	—	31,315

6-mo decomposition (Form 4)	Txns	Shares	Value	Signal weight
P — Open-market purchases	3	11,650	$0.9M	Counted
M — Exercises (paired A/D)	6	16,288	—	None — mechanics
F — Tax withholding	3	873	$0.1M	None — compensation
G — Gifts	3	9,072	—	None

Monthly Net Insider Flow (000 shares)

Net of acquisitions minus dispositions, all Form 4 types.

Signal Summary

SignalNet Buying

Open-Market Sells$0.0M0 txns / 6 mo

Open-Market Buys$0.9M3 txns / 6 mo

ClusterNone active3+ insiders / 21 days

Filed	Filer	Shares registered	Est. proceeds
2026-02-17	Peck Kristin C	20,000	$2.5M
2026-02-17	Polzer Robert J	2,346	$0.3M
2026-02-13	Polzer Robert J	3,662	$0.5M
2025-06-03	Lagano Roxanne	652	$0.1M
Trailing 12 mo	3 filings	26,008	$3M

Filed	Form	Reporting person	% of class	Shares
2026-04-30	SCHEDULE 13G	Vanguard Capital Management	7.17%	30.3M sh
2026-04-29	SCHEDULE 13G	Vanguard Portfolio Management	5.70%	24.1M sh
2026-03-27	SCHEDULE 13G/A	The Vanguard Group	—	exit/reporting change
2026-01-07	SCHEDULE 13G/A	The Vanguard Group	10.84%	47.8M sh

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Member	Chamber	Trade	Size band	Traded	Disclosed
Ro Khanna	House	SELL	$1,001 - $15,000	2026-09-25	2026-10-09
Gilbert Cisneros	House	BUY	$1,001 - $15,000	2026-09-18	2026-10-13
Gilbert Cisneros	House	BUY	$1,001 - $15,000	2026-09-18	2026-10-12
Markwayne Mullin	Senate	SELL	$15,001 - $50,000	2025-11-10	2025-12-05
Markwayne Mullin	Senate	SELL	$15,001 - $50,000	2025-11-10	2025-12-04
Markwayne Mullin	Senate	BUY	$50,001 - $100,000	2025-05-13	2025-06-11

House 12-Mo41 trades29 purchases

Senate 12-Mo2 trades0 purchases

CoverageSTOCK Act filings30-45 day disclosure lag

13F Filers (last complete Q)1,602

13F Shares407M97.4% of shares out

New / Closed162 / 189positions, QoQ

Increased / Reduced619 / 627positions, QoQ

Put/Call (13F)0.91option positions

Free Float99.8%412M sh

2.8 · Largest Reporting 13F Managers

Manager	Shares	Value
Confluence Investment Management L	1.9M	$130M
Banque Pictet & Cie Sa	1.8M	$125M
Smead Capital Management, Inc.	1.6M	$110M
Montrusco Bolton Investments Inc.	819,278	$57M
Seilern Investment Management Ltd	454,608	$32M
Assenagon Asset Management S.A.	439,483	$31M

EDGAR 13F holdings as of 2026-09-30; filer values normalized to dollars.

2.9 · Top ETF & Fund Ownership

Fund	Weight	Position
VITSX	0.0%	$825M
VTSAX	0.0%	$825M
VTI	0.0%	$825M
VSMPX	0.0%	$825M
VFIAX	0.0%	$758M
VFINX	0.0%	$758M

13F Filers Holding ZTS — quarterly

Institutional Put/Call — quarterly

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Daily short-sale volume as % of volume reported in FINRA's short-sale file — a flow measure, not short interest; dashed = 50-day average.

Latest Session36.1%2026-10-15

20-Day Avg46.1%50-day 43.8%

TrendRising20d vs 50d

By Market CenterQ: 35% · B: 49% · N: 33%latest session

Weekly Notional ($B)

Where ZTS Trades in the Dark

ATS Venue (4-wk)	Shares	Avg trade
Ubsa Ubs Ats	4.6M	57 sh
Incr Intelligent Cross Llc	4.5M	52 sh
Sgmt Sigma X2	2.6M	53 sh
Ebxl Level Ats	2.6M	34 sh
Mstx Ms Trajectory Cross (Ats-1)	1.9M	45 sh
Mlix Instinct X	1.6M	75 sh

Where a dollar of Zoetis Inc. revenue goes. All values FY2025 filings, live.

Region	Revenue	Share
United States	$5.1B	55%
International	$4.3B	45%

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

ZTS (live moat model)Peer median: TEVA · VTRS · ELAN · ALKS · LNTH

Component scores from the live moat model. Peer median illustrative.

Moat score 74/100 — Wide; primary source Efficient Scale.

3.8 · Employees (SEC filings)

Officer	Title
Kristin C. Peck	Chief Executive Officer & Director
Wetteny N. Joseph	Special Advisor to the CEO
Jamie Brannan	Executive Vice President & Chief Commercial Officer
Robert J. Polzer	Scientific Advisor

Revenue ($B)

EPS ($) — GAAP diluted actual, street-basis estimate

Actual bars are GAAP diluted EPS from the filed income statement; the lighter forward bars are street-basis consensus. The two are different measures and are not comparable quarter to quarter.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Quarterly EPS — Actual vs. Consensus

Beats (>2%)4 of 6recent quarters

Avg Surprise+3.5%

Next Report2026-11-05

Income Quality1.10OCF ÷ net income

Beat Rate—%0 of 0 quarters

Current Streak0longest 0

Avg EPS Surprise—%median —%

Surprise Trend—last 4 vs prior 4

Period	EPS est.	EPS actual	EPS surprise	Rev est. ($M)	Rev actual ($M)	Rev surprise

Announcement dates to . Consensus as it stood at each report. Revenue surprise shown where both estimate and actual are filed. A beat record is history, not a forecast.

Profit Margins (%)

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Revenue by Segment — Stacked

Live segmentation data.

YoY Growth Heatmap — Income Lines

YoY growth	FY21	FY22	FY23	FY24	FY25
Revenue	+16.5%	+3.9%	+5.7%	+8.3%	+2.3%
Gross profit	+19.2%	+3.1%	+6.5%	+9.6%	+4.3%
Operating income	+23.5%	+4.5%	+4.8%	+10.5%	+6.0%
Net income	+24.4%	+3.8%	+10.9%	+6.1%	+7.5%

$B · FY ends	FY21	FY22	FY23	FY24	FY25
Revenue	7.8	8.1	8.5	9.3	9.5
Cost of revenue	2.5	2.6	2.7	2.9	2.8
Gross profit	5.3	5.5	5.8	6.4	6.7
R&D expense	0.5	0.5	0.6	0.7	0.7
SG&A expense	2.0	2.0	2.2	2.3	2.4
Operating income	2.8	2.9	3.1	3.4	3.6
EBITDA	3.2	3.4	3.7	3.9	4.1
D&A	0.4	0.5	0.5	0.5	0.5
Pretax income	2.5	2.7	2.9	3.1	3.4
Income tax	0.5	0.5	0.6	0.6	0.7
Net income	2.0	2.1	2.3	2.5	2.7
Diluted EPS ($)	4.27	4.49	5.07	5.47	6.02
Diluted shares (M)	477	470	462	455	444

Operating CF$3B

CapEx$1B

Free cash flow$2B

SBC$0B

Buybacks$3B

Net cash change$0B

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Balance Sheet — Full

$B	FY22	FY23	FY24	FY25
Cash & equivalents	3.6	2.0	2.0	2.3
ST investments	0.0	0.0	0.0	0.0
Receivables (net)	1.2	1.3	1.3	1.6
Total current assets	7.5	6.3	6.0	6.8
PP&E (net)	3.0	3.4	3.6	4.0
Goodwill + intangibles	4.1	4.1	3.9	3.8
Total assets	14.9	14.3	14.2	15.5
Accounts payable	0.4	0.4	0.4	0.5
Short-term debt	1.4	0.0	1.4	0.1
Deferred revenue	0.0	0.0	0.0	0.0
Total current liabilities	3.2	1.9	3.4	2.2
Long-term debt	6.6	6.6	5.2	9.2
Total liabilities	10.5	9.3	9.5	12.1
Shareholders' equity	4.4	5.0	4.8	3.3

Cash Flow Statement — Full

$B	FY22	FY23	FY24	FY25
Net income	2.1	2.3	2.5	2.7
D&A	0.5	0.5	0.5	0.5
Stock-based compensation	0.1	0.1	0.1	0.1
Working capital change	(0.7)	(0.5)	0.1	(0.4)
Operating cash flow	1.9	2.4	3.0	2.9
Capital expenditures	(0.6)	(0.7)	(0.7)	(0.6)
Investing cash flow	(0.9)	(0.8)	(0.3)	(0.7)
Buybacks	(1.6)	(1.1)	(1.9)	(3.2)
Dividends paid	(0.6)	(0.7)	(0.8)	(0.9)
Debt issuance / (repay)	1.4	(1.3)	(0.0)	2.3
Financing cash flow	(0.9)	(3.1)	(2.7)	(1.9)
Free cash flow	1.3	1.6	2.3	2.3

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Balance Sheet Structure ($B)

Cash Generation vs Capex ($B)

Left: what the balance sheet is made of — the gap between the assets bar and the liabilities bar is book equity. Right: whether the capex bar is covered by the operating-cash bar; where it is not, the difference was funded externally and free cash flow goes negative.

Ratio	FY21	FY22	FY23	FY24	FY25	TTM
PROFITABILITY
ROE	49.0%	47.3%	49.9%	50.9%	66.0%	69%
ROA	14.8%	14.7%	16.0%	17.4%	18.0%	17.4%
ROIC	29.4%	26.1%	25.2%	28.4%	27.2%	21.6%
Gross margin	68.3%	67.8%	68.3%	69.1%	70.5%	70.9%
Operating margin	36.0%	36.2%	35.9%	36.6%	38.0%	37.0%
Net margin	26.2%	26.2%	27.4%	26.9%	28.2%	27.5%
EBITDA margin	40.8%	41.6%	43.1%	41.8%	43.0%	42.0%
FCF margin	22.3%	16.4%	19.0%	24.8%	24.1%	—
VALUATION
P/E	54.76	31.33	37.85	29.18	20.65	13.0
P/B	24.55	15.04	17.76	15.21	16.57	10.5
P/S	14.35	8.20	10.39	7.84	5.83	3.44
P/FCF	64.26	49.95	54.74	31.56	24.17	13.9
EV/EBITDA	36.20	21.07	25.39	19.96	15.29	10.2
EV/Revenue	14.77	8.76	10.94	8.35	6.59	4.3
Earnings yield	1.8%	3.2%	2.6%	3.4%	4.8%	7.90%
FCF yield	1.6%	2.0%	1.8%	3.2%	4.1%	7.22%

Ratio	FY21	FY22	FY23	FY24	FY25	TTM
LEVERAGE & SOLVENCY
Current ratio	3.86	2.37	3.36	1.75	3.03	3.08
Quick ratio	2.79	1.63	2.00	1.08	1.94	1.84
Debt / equity	1.48	1.84	1.35	1.41	2.85	2.93
Debt / assets	48.5%	54.2%	47.3%	47.4%	61.4%	61.3%
Net debt / EBITDA	1.03	1.34	1.28	1.23	1.76	1.94
Interest coverage	11.54	12.21	12.60	13.95	15.09	—

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Ratio	FY21	FY22	FY23	FY24	FY25	TTM
EFFICIENCY
Asset turnover	0.57	0.56	0.58	0.65	0.64	0.63
Receivables turnover	7.25	6.88	6.78	7.07	6.52	6.1
DSO (days)	50	53	54	52	56	60
DPO (days)	66	59	55	54	60	60
Cash conversion cycle	247	293	329	309	305	340
GROWTH (YoY)
Revenue growth	16.5%	3.9%	5.7%	8.3%	2.3%	—
Net income growth	24.4%	3.8%	10.9%	6.1%	7.5%	—
EPS growth	25.0%	5.7%	12.5%	8.2%	10.6%	—
FCF growth	3.8%	-23.6%	22.2%	41.8%	-0.7%	—
PER SHARE ($)
EPS (diluted, TTM)	4.28	4.53	5.09	5.51	6.09	6.26
Book value / share	9.55	9.44	10.86	10.57	7.59	7.54
Revenue / share	16.35	17.31	18.57	20.52	21.58	22.79
FCF / share	3.65	2.84	3.52	5.09	5.21	5.67
Cash / share	7.32	7.66	4.43	4.40	5.27	4.01
SHAREHOLDER RETURN & SCORES
Buyback yield	0.7%	2.4%	1.2%	2.6%	5.9%	12.14%
Altman Z-Score	9.53	6.12	8.45	7.42	5.70	4.8
Piotroski F-Score	9	5	8	7	7	7/9
Beneish M-Score	-2.49	-2.31	-2.40	-2.64	-2.36	-2.55

Model	Score	Zone	Note
Piotroski F-Score	7 / 9	Strong
Altman Z-Score	4.8	Safe (>2.99)	Safe
Income quality	1.10	Cash-backed	OCF ÷ net income
Beneish M-Score	-2.55	Non-manipulator	vs −2.22 threshold

DuPont Decomposition (TTM)	Value
Tax burden	0.80
Interest burden	0.93
Operating margin	36.9%
Asset turnover	0.64×
Financial leverage	3.64×
= ROE	64%

Growth Quality (live)	Value
Revenue stability	0.97
Earnings stability	0.97
Earnings persistence	1.00
Revenue CAGR 3y	5.0%
EPS CAGR 3y	9.4%
FCF CAGR 3y	22.6%

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Buyback Yield12.14%

Dividend Yield2.63%

Total Shareholder Return15.10%cash yield

SBC / Revenue1.0%dilution pressure

Company	Mkt cap	P/E	ROE	Net margin	Rev growth	Piotroski	1-yr ret
TEVA	$48.4B	65.4	10%	-13.9%	+4.1%	7/9	+111.4%
VTRS	$21.4B	-51.8	-3%	-3.2%	+4.4%	7/9	+87.0%
ELAN	$11.8B	-57.4	-3%	3.9%	+12.0%	5/9	+14.8%
ALKS	$6.9B	102.3	4%	0.1%	+10.8%	4/9	+33.8%
LNTH	$6.5B	23.7	22%	19.3%	+2.3%	5/9	—
AMRX	$6.1B	38.6	-396%	7.2%	+9.3%	8/9	—
INDV	$4.0B	11.4	-152%	35.6%	+13.5%	4/9	—
MTD	$32.5B	36.4	-736%	22.7%	+6.9%	8/9	—

1-yr returns computed from adjusted price history; peers without a tracked series show —.

Hold

32 Analysts

Str Sell (0)Sell (0)Hold (17)Buy (14)Str Buy (1)

Mean Target (qtr)$86.176 targets

Target vs. Price+8.6%last-quarter mean

Next Report2026-11-05street $1.51

Consensus estimates	Revenue mean	High / Low	EPS mean	High / Low	# EPS est.
FY2026	$9.25B	$9.42B / $9.11B	$6.21	$6.31 / $5.72	10
FY2027	$9.40B	$9.77B / $8.97B	$6.41	$6.83 / $6.04	11
FY2028	$9.78B	$10.99B / $9.00B	$6.92	$8.10 / $5.64	6

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Street Price Target — Trajectory

Window	Avg Target	vs. Price	# Targets
Last Month	$74.00	-6.7%	1
Last Quarter	$86.17	+8.6%	6
Last Year	$113.23	+42.8%	22
All Time	$149.51	+88.5%	35

Rolling mean of published targets vs. last close $79.32. Aggregated from StreetInsider, Benzinga, Pulse 2.0.

Third-Party Composite Rating

A-

DCF

5/5

ROE

5/5

ROA

5/5

Debt/Eq

1/5

P/E

3/5

P/B

1/5

Independent quant composite as of 2026-10-16; components scored 1–5 (5 best). Shown for contrast with the InsiderStreet Score — methodologies differ.

ZTS -44.4% vs S&P 500 +15.9% — spread -60.3pp

Sector — XLV +24.2%

Peer Set — indexed to 100

All series indexed to 100 at the start of the window, adjusted closes.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Candlesticks with SMA 20/50 overlay, Bollinger (20,2σ) band, volume, and Wilder RSI(14) — computed from live daily OHLCV.

Moving Average	Value	Distance	% Distance	Signal
SMA 20	$72.63	+6.69	+9.21%	Above
SMA 50	$73.98	+5.34	+7.22%	Above
SMA 200	$95.78	-16.46	-17.19%	Below
EMA 9	$75.48	+3.84	+5.09%	Above
EMA 21	$73.96	+5.36	+7.25%	Above
EMA 50	$74.51	+4.81	+6.46%	Above
EMA 200	$93.08	-13.76	-14.78%	Below

Series and readings from the nightly technical-indicator history — identical data to the site's ribbon chart. Supertrend segments colored by direction.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

TECHNICAL VERDICTBULLISHPower Score +6420 of 22 indicator votes bullish

Family Scores (site weights)

Trend 30%78

Momentum 25%100

Volume 20%81

Volatility 10%100

Patterns 15%50

This Week82% bullishof 11 price-based votes

4 Weeks Ago0%+82 pts since

12 Weeks Ago0%+82 pts since

ReadImprovingweek-over-week trajectory

Price vs SMA 20$72.63

Price vs SMA 50$73.98

Price vs SMA 200$95.78

EMA 9/21 Cross75.5/74.0

SMA 50/200Death

ADX DirectionADX 23

Supertrend$73

Parabolic SAR$73

SMA Slope0.400

RSI69.4

Stochastic K/D91/89

StochRSI K/D96/91

Williams %R-10

CCI212

TSI vs Signal13.8

CMO38.7

ROC13.88%

OBV SignalAccum

Chaikin MF0.090

MFI64

Force Index4M

Elder Ray Bull6.63

RSI (14)30 oversold · 70 overbought

Stochastic %Kvs %D 89

Money Flowvolume-weighted RSI

ADXtrend strength · <20 weak

Williams %Rinverted scale

Level	Value	Level	Value
Pivot / R1 / R2	$78.03 / $79.54 / $80.66	S1 / S2	$76.91 / $75.40
Bollinger (20,2)	$67.09 – $78.18	Squeeze	Off
52-wk range	$68.77 – $147.79	Off 52-wk high	-46.3%
ATR (14)	$2.01 (2.5%)	Historical vol	26.4%

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

-0.8%Jan46%

+1.6%Feb50%

-3.0%Mar21%

+2.4%Apr69%

+2.4%May62%

+0.7%Jun46%

+3.0%Jul77%

+1.2%Aug77%

-0.9%Sep54%

-1.0%Oct38%

+3.3%Nov54%

+1.7%Dec54%

Sample: 13 years — treat short histories as suggestive, not statistical.

Computed from live weekly prices	ZTS	S&P 500
Weekly volatility (σ, 1y)	6.07%	1.83%
Best / worst week (1y)	+10.6% / -27.4%	—
Max drawdown (5y, monthly)	-68.3%	—
1-week VaR (95%)	-12.9%	—
Beta (5y)	0.73	1.00

ZTS EQUITY WEATHER (LIVE)PARTLY CLOUDY · +22

Trend+27

Momentum+70

Volume+40

Volatility-60

Breadth-30

MARKET REGIME (2026-10-16)NEUTRAL

VIX19.99Normal

Dow TheoryConfirmed Bearish

SPY / QQQ TSI7.2 / 4.7trend strength

Sector Strength46/100breadth average

Average sentiment of 244 stories, weekly buckets, −1 to +1.

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Overall+21.6+41.4 vs industry

Trend+26.9+47.9 vs industry

Momentum+70.1+94.6 vs industry

Volume+40.0+56.9 vs industry

Reading	ZTS	Drug Manufacturers - Specialty & Generic n=977	Healthcare n=5,272	All US symbols n=70,435
Overall	+21.6	-19.9	-24.0	-20.5
Trend	+26.9	-21.0	-25.6	-21.3
Momentum	+70.1	-24.6	-28.5	-15.8
Volume	+40.0	-16.9	-25.0	-3.8

Trend, momentum and volume are computed per company. Volatility and breadth are market-regime values shared by every symbol in the universe, so they are reported once under Market Regime rather than compared here - a company cannot differ from its sector on a constant.

Executive	Total comp	Structure
Kristin C. Peck Chief Executive Officer	$17.2M	71% equity+incentive
Wetteny Joseph Executive Vice President (“EV	$5.1M	67% equity+incentive
Heidi C. Chen Former EVP, General Counsel an	$3.6M	38% equity+incentive
Jamie Brannan EVP and Chief Commercial Offic	$3.0M	55% equity+incentive
Robert J. Polzer EVP and President of Resear	$3.0M	61% equity+incentive

Pillar (live disclosure scores)	Score
Environmental	53
Social	44
Governance	60
Composite ESG	52

Composite ESG Trend

Filed	8-K contents	Items
2026-10-13	Officer/Director Change; Regulation FD; Exhibits	5.02,7.01,9.01
2026-10-08	Regulation FD; Exhibits	7.01,9.01
2026-08-06	Earnings Release; Exhibits	2.02,9.01
2026-08-06	Officer/Director Change; Exhibits	5.02,9.01
2026-05-22	Officer/Director Change; Shareholder Vote	5.02,5.07
2026-05-20	Regulation FD; Exhibits	7.01,9.01
2026-05-07	Earnings Release; Exhibits	2.02,9.01
2026-02-12	Results of Operations and Financial Condition; Financial Statements an	2.02,9.01

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Methodology. Every figure originates in InsiderStreet's production data layer and is computed deterministically by the same engines that power insiderstreet.ai. This factsheet contains no model-written text. Sections without underlying data are omitted rather than estimated.

DISCLOSURES. This document is produced by InsiderStreet.ai from live production data. It is not investment advice, not an offer or solicitation to buy or sell any security, and not a recommendation tailored to any person. Data is sourced as of the dates shown and may no longer be current. InsiderStreet.ai is not a registered investment adviser or broker-dealer. Investing involves risk, including loss of principal. Past performance does not guarantee future results. Do not make any investment decision based on this document. © 2026 InsiderStreet.ai — all rights reserved. Redistribution prohibited.

Data domain	Source	Coverage for this report
Price & volume	market_db.historical_prices	52 rows
Fundamentals	income_statements_annual	6 rows · 2020 to 2025
Reported vs consensus	fact/earnings_calendar	24 rows · 2020-11-05 to 2026-08-06
Analyst estimates	dim/forward_estimates	3 rows · 2026-12-31 to 2028-12-31
Institutional ownership (13F)	holdings_db.institutional_ownership_summary	60 rows · 2010 to 2026
Insider transactions (Form 4)	edgar/form4	12 rows · 2026-09-17 to 2026-10-09
Proposed sales (Form 144)	edgar/form144	1 record
Beneficial ownership (13D/G)	edgar/13dg	4 rows · 2026-01-07 to 2026-04-30
Short-sale volume (FINRA)	edgar/short_volume_daily	60 rows · 2026-07-23 to 2026-10-15
Dark pool (ATS, tier 1)	edgar/darkpool_weekly	12 rows · 2026-06-15 to 2026-08-31
ETF & fund holding	etf_holdings_changelog (30d)	1 record
Peer set	stock_peers_dynamic	8 rows
Industry medians	industry_medians	1 record
Congressional trades	congress_db (House + Senate)	1 record
ESG	fact/esg_disclosures	1 record

Method. Every figure in this factsheet is looked up from a named field computed in code. It contains no model-written text.

Not covered. Short interest as a percent of float and days-to-cover are not in this data set — the short-sale figures above are FINRA volume, a flow, and cannot support squeeze or covering analysis. Options positioning and intraday data are also absent. 13F ownership is filed 45 days after quarter end and congressional trades are disclosed on a lag, so both describe a past position, not a current one.

Zoetis Inc. (ZTS)

Zoetis Inc. (ZTS)

Score Breakdown

Peer Comparison — IS Score

IS Score Trend — quarterly

Zoetis Inc. (ZTS)

Institutions holding — 12 quarters

Zoetis Inc. (ZTS)

Monthly Net Insider Flow (000 shares)

Signal Summary

Zoetis Inc. (ZTS)

2.8 · Largest Reporting 13F Managers

2.9 · Top ETF & Fund Ownership

13F Filers Holding ZTS — quarterly

Institutional Put/Call — quarterly

Zoetis Inc. (ZTS)

Where ZTS Trades in the Dark

Zoetis Inc. (ZTS)

3.8 · Employees (SEC filings)

Zoetis Inc. (ZTS)

Zoetis Inc. (ZTS)

Zoetis Inc. (ZTS)

Balance Sheet — Full

Cash Flow Statement — Full

Zoetis Inc. (ZTS)

Zoetis Inc. (ZTS)

Zoetis Inc. (ZTS)

Zoetis Inc. (ZTS)

Street Price Target — Trajectory

Third-Party Composite Rating

Zoetis Inc. (ZTS)

Zoetis Inc. (ZTS)

Family Scores (site weights)

Zoetis Inc. (ZTS)

Zoetis Inc. (ZTS)

Zoetis Inc. (ZTS)